Curriculum Vitaes
Profile Information
- Affiliation
- lecturer, Gastrointestinal Surgery, Fujita Health University
- Degree
- Ph.D.(Niigata University)
- Researcher number
- 30757505
- J-GLOBAL ID
- 201801017968110630
- researchmap Member ID
- B000302641
2007年(平成19年)4月より新潟大学医歯学総合病院消化器・一般外科勤務
2015年(平成27年)6月より新潟大学医歯学総合病院光学医療診療部助教
2018年(平成30年)10月より藤田医科大学総合消化器外科講師(国内留学)
2015年(平成27年)6月より新潟大学医歯学総合病院光学医療診療部助教
2018年(平成30年)10月より藤田医科大学総合消化器外科講師(国内留学)
Research Areas
1Papers
241-
International journal of clinical oncology, 29(6) 790-800, Jun, 2024BACKGROUND: Initial chemotherapy (Initial-C) followed by surgery is a promising treatment strategy for peritoneal lavage cytology-positive gastric cancer (CY1 GC) with no other noncurative factors. The aim of this study was to investigate the survival advantage of Initial-C compared to initial surgery (Initial-S) for this disease according to the macroscopic type, which was associated with prognosis and the efficacy of chemotherapy in GC. METHODS: One hundred eighty-nine patients who were diagnosed with CY1 GC with no other noncurative factors at four institutions from January 2007 to December 2018 were enrolled. The patients were divided into a macroscopic type 4 group (N = 48) and a non-type 4 group (N = 141). The influence of initial treatment on overall survival (OS) in each group was evaluated. RESULTS: In the type 4 group, the 5-year OS rates of Initial-C (N = 35) and Initial-S (N = 13) were 11.6% and 0%, respectively (P = 0.801). The multivariate analysis could not show the survival advantage of Initial-C. In the non-type 4 group, the 5-year OS rates of Initial-C (N = 41) and Initial-S (N = 100) were 48.4% and 29.0%, respectively (P = 0.020). The multivariate analysis revealed that Initial-C was independently associated with prolonged OS (hazard ratio, 0.591; 95% confidence interval, 0.375-0.933: P = 0.023). CONCLUSIONS: Initial-C improves the prognosis of non-type 4 CY1 GC with no other noncurative factors. On the other hand, further development of effective chemotherapeutic regimens and innovative treatment strategies are required for type 4 CY1 GC.
Misc.
338-
日本内視鏡外科学会雑誌, 25(7) WS29-3, Mar, 2021
-
日本内視鏡外科学会総会(Web), 33rd, 2021
-
日本消化器外科学会雑誌(Web), 54(Supplement1), 2021
Research Projects
10-
科学研究費助成事業, 日本学術振興会, Apr, 2023 - Mar, 2026
-
科学研究費助成事業, 日本学術振興会, Jun, 2022 - Mar, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025